Financial Performance - Lexeo Therapeutics reported cash and cash equivalents of $175.0 million as of June 30, 2024, expected to fund operations into 2027[4] - Research and development (R&D) expenses increased to $16.6 million for Q2 2024, up from $11.2 million in Q2 2023, representing a 48% increase[4] - General and administrative (G&A) expenses rose to $7.0 million in Q2 2024, compared to $2.7 million in Q2 2023, marking a 159% increase[4] - The net loss for Q2 2024 was $21.2 million, or $0.64 per share, compared to a net loss of $13.4 million, or $8.30 per share, in Q2 2023[4] Clinical Development - Interim data from the Phase 1/2 studies of LX2006 showed sustained improvements across multiple cardiac biomarkers in Friedreich ataxia cardiomyopathy[2] - LX2006 was well tolerated with no treatment-related serious adverse events reported to date[3] - Lexeo initiated formal engagements with the FDA regarding surrogate endpoints for a registrational study of LX2006, with an update expected by the end of 2024[3] - The company plans to share additional data from LX2006 at a scientific conference in Fall 2024[4] - Interim data readout for LX2020 (HEROIC-PKP2) is expected in the second half of 2024[4] Leadership Changes - Tim Van Hauwermeiren was appointed to the Board of Directors in July 2024, bringing over 20 years of experience in life sciences[3]

Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; ...

Data from the SUNRISE-FA study showed that treatment with LX2006 achieved a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline. LVMI is an estimator of cardiac morbidity and mortality. Treatment with the therapy was also well-tolerated across all study participants, with no treatment-related serious adverse events. Shares of Lexeo Therapeutics (LXEO) lost 26% on Monday after it reported positive interim data from t ...

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness and troponin I, in majority of participants at 12 months Increased post-treatment frataxin expression above baseline in all participants evaluated ...

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness and troponin I, in majority of participants at 12 months Increased post-treatment frataxin expression above baseline in all participants evaluated ...

"Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "Tim's deep and relevant experience in company building from clinical to commercial stage will be an invaluable asset to Lexeo as we embark on our next phase of growth and progress our pipeline into later stages of clinical and commercial development." "I am ...

Investors might want to bet on Lexeo Therapeutics, Inc. (LXEO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following year ...

Lexeo Therapeutics, Inc. (LXEO) closed the last trading session at $13.56, gaining 12.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.40 indicates a 57.8% upside potential. The average comprises five short-term price targets ranging from a low of $19 to a high of $24, with a standard deviation of $2.07. While the lowest estimate indicates an increase of 40.1% from the curren ...

Exhibit 99.1 Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim read ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR | Delaware | 85-4012572 | | --- | --- | | ( ...